PT3351539T - Complexo cristalino de mono-hidrato de 1-ciano-2-(4- ciclopropil-benzil)-4-(beta-d-glucopiranos-1-il)-benzeno e lprolina em água cristalina (1:1:1), métodos para a sua preparação e a sua utilização como um inibidor de sglt - Google Patents

Complexo cristalino de mono-hidrato de 1-ciano-2-(4- ciclopropil-benzil)-4-(beta-d-glucopiranos-1-il)-benzeno e lprolina em água cristalina (1:1:1), métodos para a sua preparação e a sua utilização como um inibidor de sglt

Info

Publication number
PT3351539T
PT3351539T PT181550799T PT18155079T PT3351539T PT 3351539 T PT3351539 T PT 3351539T PT 181550799 T PT181550799 T PT 181550799T PT 18155079 T PT18155079 T PT 18155079T PT 3351539 T PT3351539 T PT 3351539T
Authority
PT
Portugal
Prior art keywords
glucopyranos
proline
cyclopropyl
cyano
beta
Prior art date
Application number
PT181550799T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh
Publication of PT3351539T publication Critical patent/PT3351539T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26Acyclic or carbocyclic radicals, substituted by hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04Carbocyclic radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PT181550799T 2012-07-26 2013-07-25 Complexo cristalino de mono-hidrato de 1-ciano-2-(4- ciclopropil-benzil)-4-(beta-d-glucopiranos-1-il)-benzeno e lprolina em água cristalina (1:1:1), métodos para a sua preparação e a sua utilização como um inibidor de sglt PT3351539T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12177944 2012-07-26

Publications (1)

Publication Number Publication Date
PT3351539T true PT3351539T (pt) 2023-01-17

Family

ID=48874313

Family Applications (2)

Application Number Title Priority Date Filing Date
PT181550799T PT3351539T (pt) 2012-07-26 2013-07-25 Complexo cristalino de mono-hidrato de 1-ciano-2-(4- ciclopropil-benzil)-4-(beta-d-glucopiranos-1-il)-benzeno e lprolina em água cristalina (1:1:1), métodos para a sua preparação e a sua utilização como um inibidor de sglt
PT13740309T PT2877460T (pt) 2012-07-26 2013-07-25 COMPLEXO CRISTALINO DE 1-CIANO-2-(4-CICLOPROPIL-BENZIL)-4-(ß-D-GLUCOPIRANOS-1-IL)-BENZENO, MÉTODOS PARA A SUA PREPARAÇÃO E A SUA UTILIZAÇÃO PARA PREPARAR MEDICAMENTOS

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT13740309T PT2877460T (pt) 2012-07-26 2013-07-25 COMPLEXO CRISTALINO DE 1-CIANO-2-(4-CICLOPROPIL-BENZIL)-4-(ß-D-GLUCOPIRANOS-1-IL)-BENZENO, MÉTODOS PARA A SUA PREPARAÇÃO E A SUA UTILIZAÇÃO PARA PREPARAR MEDICAMENTOS

Country Status (23)

Country Link
US (1) US9145434B2 (enExample)
EP (3) EP4166548A1 (enExample)
JP (2) JP6538556B2 (enExample)
CN (2) CN108774200A (enExample)
AR (1) AR091908A1 (enExample)
AU (1) AU2013294947B2 (enExample)
BR (1) BR112015001327B1 (enExample)
CA (1) CA2878698C (enExample)
DK (2) DK3351539T3 (enExample)
EA (2) EA025438B1 (enExample)
ES (2) ES2937665T3 (enExample)
FI (1) FI3351539T3 (enExample)
HR (2) HRP20230081T1 (enExample)
HU (1) HUE061450T2 (enExample)
LT (1) LT3351539T (enExample)
MX (1) MX357906B (enExample)
PL (2) PL3351539T3 (enExample)
PT (2) PT3351539T (enExample)
RS (1) RS63881B1 (enExample)
SG (1) SG11201500574QA (enExample)
SI (2) SI2877460T1 (enExample)
TW (1) TW201418275A (enExample)
WO (1) WO2014016381A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9145434B2 (en) 2012-07-26 2015-09-29 Boehringer Ingelheim International Gmbh Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments
EP2981269B9 (en) 2013-04-04 2023-12-06 Boehringer Ingelheim Vetmedica GmbH Treatment of metabolic disorders in equine animals
PL3082829T3 (pl) * 2013-12-17 2021-09-06 Boehringer Ingelheim Vetmedica Gmbh Inhibitory sglt2 do leczenia zaburzeń metabolicznych u zwierząt kotowatych
PL3096765T3 (pl) 2014-01-23 2019-05-31 Boehringer Ingelheim Vetmedica Gmbh Leczenie zaburzeń metabolicznych u zwierząt psowatych
KR102662473B1 (ko) 2014-04-01 2024-05-03 베링거잉겔하임베트메디카게엠베하 말과 동물에서 대사 장애의 치료
CN103965020B (zh) * 2014-05-06 2015-09-09 启东东岳药业有限公司 制备5-碘-2-溴苄醇的方法
AU2015320975B2 (en) 2014-09-25 2020-10-08 Boehringer Ingelheim Vetmedica Gmbh Combination treatment of SGLT2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals
KR20170060035A (ko) * 2014-09-30 2017-05-31 지앙수 헨그루이 메디슨 컴퍼니 리미티드 나트륨 글루코스 공동운반체 2 억제제의 l- 프롤린 화합물, 및 l- 프롤린 화합물의 모노하이드레이트 및 결정
CZ2015110A3 (cs) * 2015-02-18 2016-08-31 Zentiva, K.S. Pevné formy empagliflozinu
NZ739429A (en) 2015-08-27 2023-03-31 Boehringer Ingelheim Vetmedica Gmbh Liquid pharmaceutical compositions comprising sglt-2 inhibitors
WO2017203457A1 (en) * 2016-05-26 2017-11-30 Dr. Reddy's Laboratories Limited Solid state forms of empagliflozin
KR102226465B1 (ko) * 2016-05-28 2021-03-11 하이난 수안주 파마 코포레이션 리미티드 나트륨-글루코스 공수송체 2에 대한 억제제의 결정형
EP3668846A1 (en) * 2017-12-19 2020-06-24 Boehringer Ingelheim Vetmedica GmbH Synthesis of the 1 :1 :1 co-crystal of 1 -cyano-2-(4-cyclopropyl-benzyl)-4-(beta-d-glucopyranos-1 -yl)-benzene, l-proline and water
US11759474B2 (en) 2019-11-28 2023-09-19 Boehringer Ingelheim Vetmedica Gmbh Use of SGLT-2 inhibitors in the drying-off of non-human mammals
CN118615450A (zh) 2020-02-17 2024-09-10 勃林格殷格翰动物保健有限公司 Sglt-2抑制剂用于预防和/或治疗猫科动物的心脏疾病的用途
WO2023006718A1 (en) 2021-07-28 2023-02-02 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in non-human mammals excluding felines, in particular canines
CA3224673A1 (en) 2021-07-28 2023-02-02 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals
WO2023006745A1 (en) 2021-07-28 2023-02-02 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
AU2023277704A1 (en) 2022-05-25 2024-12-05 Boehringer Ingelheim Vetmedica Gmbh Aqueous pharmaceutical compositions comprising sglt-2 inhibitors
AU2024233233A1 (en) 2023-03-06 2025-09-11 Boehringer Ingelheim Vetmedica Gmbh Systems for delivery of liquid pharmaceutical compositions in particular comprising one or more sglt-2 inhibitor(s)
CN121039113A (zh) 2023-04-24 2025-11-28 勃林格殷格翰动物保健有限公司 维格列净与所选共晶形成剂的结晶复合物、其制备方法及其在制备药物中的用途
WO2024240632A1 (en) 2023-05-24 2024-11-28 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan
TW202508455A (zh) 2023-05-24 2025-03-01 德商百靈佳殷格翰維美迪加股份有限公司 包含一或多種sglt-2抑制劑及替米沙坦(telmisartan)之非人類哺乳動物之腎臟疾病及/或高血壓之組合治療及/或預防

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083066A2 (en) 2001-04-11 2002-10-24 Bristol-Myers Squibb Company Amino acid complexes of c-aryl glucosides for treatment of diabetes and method
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
EP1581543A4 (en) * 2003-01-03 2008-03-19 Bristol Myers Squibb Co METHODS FOR PRODUCING SGLT2 GLYCOSIS C-ARYL INHIBITORS
CN103435581B (zh) * 2004-03-16 2015-08-19 贝林格尔.英格海姆国际有限公司 吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法
DE602006018961D1 (de) * 2005-09-08 2011-01-27 Boehringer Ingelheim Pharma KRISTALLINE FORMEN VON 1-CHLORO-4-(ß-D-GLUCOPYRANOS-1-YL)-2-(4-ETHYNYL-BENZYL)-BENZOL, ZUBEREITUNGSVERFAHREN DAFÜR UND DESSEN VERWENDUNG ZUR ARZNEIMITTELHERSTELLUNG
EA200801773A1 (ru) * 2006-02-15 2009-02-27 Бёрингер Ингельхайм Интернациональ Гмбх Глюкопиранозилзамещенные производные бензонитрила, фармацевтические композиции, содержащие такие соединения, их применение и способ их получения
TWI370818B (en) * 2006-04-05 2012-08-21 Astellas Pharma Inc Cocrystal of c-glycoside derivative and l-proline
PE20080697A1 (es) * 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
US7919598B2 (en) * 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
TW200817424A (en) 2006-08-04 2008-04-16 Daiichi Sankyo Co Ltd Benzylphenyl glucopyranoside derivatives
TW200904405A (en) 2007-03-22 2009-02-01 Bristol Myers Squibb Co Pharmaceutical formulations containing an SGLT2 inhibitor
EP2147008A2 (en) * 2007-05-18 2010-01-27 Bristol-Myers Squibb Company Crystal structures of sglt2 inhibitors and processes for preparing same
CN103319445B (zh) * 2007-12-27 2016-01-20 阿斯利康公司 Sglt2抑制剂的晶体结构及其制备方法
HRP20161648T1 (hr) * 2008-08-22 2017-02-10 Theracos Sub, Llc Postupak za pripravu sglt2 inhibitora
ATE540040T1 (de) 2008-08-28 2012-01-15 Pfizer Dioxabicycloä3.2.1üoctan-2,3,4-triolderivate
WO2010048358A2 (en) 2008-10-22 2010-04-29 Auspex Pharmaceutical, Inc. Ethoxyphenylmethyl inhibitors of sglt2
WO2011153712A1 (en) * 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
US9145434B2 (en) 2012-07-26 2015-09-29 Boehringer Ingelheim International Gmbh Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments
EP2981269B9 (en) 2013-04-04 2023-12-06 Boehringer Ingelheim Vetmedica GmbH Treatment of metabolic disorders in equine animals

Also Published As

Publication number Publication date
EA025438B1 (ru) 2016-12-30
CA2878698C (en) 2021-03-23
CN104470908A (zh) 2015-03-25
JP6538556B2 (ja) 2019-07-03
US20140031540A1 (en) 2014-01-30
MX2015000962A (es) 2015-04-16
WO2014016381A1 (en) 2014-01-30
BR112015001327B1 (pt) 2022-08-16
AR091908A1 (es) 2015-03-11
JP2015522644A (ja) 2015-08-06
ES2694675T3 (es) 2018-12-26
SG11201500574QA (en) 2015-02-27
EP3351539A1 (en) 2018-07-25
ES2937665T3 (es) 2023-03-30
PT2877460T (pt) 2018-12-19
DK2877460T3 (en) 2019-01-07
EA201600506A1 (ru) 2017-03-31
HRP20230081T1 (hr) 2023-03-17
SI3351539T1 (sl) 2023-03-31
EP3351539B1 (en) 2022-11-09
CA2878698A1 (en) 2014-01-30
EP4166548A1 (en) 2023-04-19
LT3351539T (lt) 2023-02-10
DK3351539T3 (da) 2023-01-30
EP2877460B1 (en) 2018-09-12
EP2877460A1 (en) 2015-06-03
MX357906B (es) 2018-07-30
SI2877460T1 (sl) 2018-12-31
AU2013294947A1 (en) 2015-01-22
BR112015001327A2 (pt) 2017-07-04
TW201418275A (zh) 2014-05-16
HUE061450T2 (hu) 2023-07-28
AU2013294947B2 (en) 2017-03-30
US9145434B2 (en) 2015-09-29
RS63881B1 (sr) 2023-02-28
PL2877460T3 (pl) 2019-04-30
FI3351539T3 (fi) 2023-02-19
JP2018135384A (ja) 2018-08-30
CN108774200A (zh) 2018-11-09
EA201500038A1 (ru) 2015-07-30
HRP20181972T1 (hr) 2019-01-25
PL3351539T3 (pl) 2023-03-06

Similar Documents

Publication Publication Date Title
PT3351539T (pt) Complexo cristalino de mono-hidrato de 1-ciano-2-(4- ciclopropil-benzil)-4-(beta-d-glucopiranos-1-il)-benzeno e lprolina em água cristalina (1:1:1), métodos para a sua preparação e a sua utilização como um inibidor de sglt
IL231386A (en) Pyrazolequinoline derivatives, their preparation and medical use
EP2669289A4 (en) QUINOLINE-LIKE COMPOUND CONTAINING A PHOSPHORUS-SUBSTITUTED GROUP, PREPARATION METHOD, MEDICAL COMPOSITION CONTAINING THE COMPOUND, AND APPLICATION
IL221160A (en) 4,2,1-triazine-3-amine derivatives, a process for their preparation and use for drug preparation
PL2590976T3 (pl) Pochodne imidazopirydyny, sposób ich wytwarzania i ich zastosowanie terapeutyczne
AP2014007670A0 (en) Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof
EP2740729A4 (en) QUINAZOLINE DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING THE COMPOUND, AND USE OF THE DERIVATIVE IN THE PREPARATION OF A MEDICAMENT
EP2933250A4 (en) PHENYL-C-GLUCOSIDE DERIVATIVE CONTAINING DEOXYGLUCOSE STRUCTURE, PREPARATION METHOD AND USE THEREOF
IL233602A0 (en) History of benzamide, their preparation and pharmaceutical preparations containing them
IL242437B (en) Compound 9, 5-dimethyl-9-hydroxy-decan-4-al, its use and its preparation process
EP2924042A4 (en) BIS-BETA-CARBOLINE COMPOUND AND METHOD OF MANUFACTURING, PHARMACEUTICAL COMPOSITION AND USE THEREOF
IL239146A0 (en) Aminocyclobutane derivatives, methods for their preparation and their use as drugs
PT2870145T (pt) Derivados de indeno, sua preparação e utilização como medicamentos
PL2851075T3 (pl) Preparat zawierający pochodną 6,7-nienasyconego-7-karbamoilomorfinanu
ZA201407214B (en) Therapeutic preparation and process for preparing said therapeutic preparation
SG11201405376TA (en) CRYSTALLINE FORMS OF 5α-ANDROSTANE-3β, 5, 6β-TRIOL AND PREPARATION METHODS THEREOF
PL398021A1 (pl) Nowa diacylo-sn-glicero-3-fosfocholina oraz sposób jej otrzymywania
PL398018A1 (pl) Nowa diacylo-sn-glicero-3-fosfocholina oraz sposób jej otrzymywania
SG2014010433A (en) Stable compositions and methods for preparing the same
PL398989A1 (pl) (Z)-6-O-ß-D-4'''-O-metylo-glukopiranozylo-4'-hydroksy-4-metoksy-7-prenyloauron i sposób jego wytwarzania
PL398987A1 (pl) (Z)-6-siarczan-6,4'-dihydroksy-7-prenylo-4-metoksyauronu i sposób jego wytwarzania
GB201112642D0 (en) Surgical hair preparation substance
HK1195303A (en) Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof
PL399423A1 (pl) Sposób wytwarzania 2'-hydroksydihydrochalkonu
PL399422A1 (pl) Sposób wytwarzania 2',4,4',6'-tetrahydroksydihydrochalkonu